Oncology and Oncohematology

Oncology and onco-hematology are one of the areas of medicine with more advancement in modern medicine. Over the past fifty years of modern oncology, we have seen scientific advances and improved outcomes for patients, significantly increasing cancer survival and quality of life.

Cancer is one of the world’s most pressing health care challenges. On the whole, research progress from one year to the next is incremental, and true breakthroughs are exceptional. Nevertheless, every year brings new knowledge and insights that help direct further research and ultimately improve the outlook for patients with cancer. Nowadays, 7 out of 10 children are now cured of cancer! Childhood cancers respond well to chemotherapy as they are usually fast growing cancers, and most forms of chemotherapy affect quickly growing cells. Children‘s bodies are also largely better able to recover from higher doses of treatment than adults‘ bodies. Two out of three people are now living at least five years after their cancer has been diagnosed. Within the last decade alone, the response rates to treatments across all cancers have nearly doubled.

However, the forces that fueled this progress are not the same as those that will shape the future. Oncology leaders, scientists and clinicians agree: we are on the verge of a new age of cancer care, in which emerging scientific, technical and economic trends are likely to alter our work more significantly in the next 20 years than in the prior 50.

GBT is already working on bringing that future to life, with medicines that support oncologic treatment in several phases and degrees. State of the art therapies, such as Vidaza, Abraxane, Bozob, Zivalix, Olvestran make a difference on hundreds of patients in the region every year.

GBT remains committed to oncology at its core and will continue to develop life-transforming medicines for the region.